Compare LEE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | ENTX |
|---|---|---|
| Founded | 1890 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 62.6M |
| IPO Year | 2025 | 2015 |
| Metric | LEE | ENTX |
|---|---|---|
| Price | $9.76 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 57.4K | ★ 93.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $543,955,000.00 | $42,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $0.91 |
| 52 Week High | $10.33 | $3.22 |
| Indicator | LEE | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 47.25 |
| Support Level | $7.95 | $1.17 |
| Resistance Level | N/A | $1.37 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 84.98 | 14.29 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.